CHS-0214: Phase III data

The 52-week, double-blind, international Phase III RApsody (CHS-0214-02) trial in about 620 patients with moderate to severe RA showed that once-weekly 50 mg subcutaneous CHS-0214 met the primary endpoint of demonstrating equivalence to 50 mg Enbrel etanercept in the proportion of patients achieving an ACR20 response at week 24. There were no clinically meaningful differences in the safety or immunogenicity profiles between treatment arms. The trial enrolled patients who had an inadequate response to methotrexate and were naive to biologic therapies. ...